

## AGENDA

*Uniform Formulary Beneficiary Advisory Panel  
22 Sept 2011 @ 0900 AM*

*Naval Heritage Center Theater  
701 Pennsylvania Ave. NW., Washington DC 20004*

- **Administrative Meeting (BAP members only @ 8:00 AM-9:00 AM)**
- **Sign-In**
- **Welcome and Opening Remarks**
- **Public Citizen Comments**
- **Therapeutic Class Reviews**

*Members of the DoD Pharmacoeconomic Center will present relative clinical and cost effective analyses along with the DoD Pharmacy & Therapeutics Committee recommendations for the Uniform Formulary.*

*The Committee made recommendations of the following drug classes during the Aug 2011 meeting:*

- *Drug Class Reviews:*
  - *Oral Non-Steroidal Anti-Inflammatory Drugs (NSAID)*
  - *Contraceptive Agents*
    - *Oral contraceptive products*
    - *Miscellaneous agents*
    - *Emergency contraceptives*
  - *Phosphodiesterase-5 Inhibitor (PDE-5) for Erectile Dysfunction (Clinical Only)*
- *Designated Newly Approved Drugs:*
  - *Renin Angiotensin Antihypertensives (RAAs)*
    - *Azilsartan - (Edarbi Tablets)*
    - *Aliskiren/amlodipine/Hydrochlorothiazide - (Amturnide Tablets)*
  - *Non-Insulin Diabetes Mellitus Agents — Bromocriptine mesylate quick release tablets (Cycloset Tablets)*
  - *Narcotic Analgesics — Buprenorphine transdermal patch - (Butrans)*

➤ *Items for Information—*

- *Singulair Prior Authorization*

➤ **Panel Discussions**

*The Uniform Formulary Beneficiary Advisory Panel will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendation and vote to accept or reject the recommendations. The Panel will provide comments on their vote as directed by the Panel Chairman.*